Prof. Igor Stagljar

Igor Stagljar is a Professor at the Donnelly Centre for Cellular and Biomolecular Research, University of Toronto. Following his training at ETH Zurich, he established an internationally recognized research program at the intersection of cancer biology, proteomics, and drug discovery. His laboratory pioneered innovative live-cell platforms to map protein–protein interactions and complex disease signaling networks, enabling systematic interrogation of previously hard-to-study targets. His translational research has contributed to new therapeutic strategies for drug-resistant EGFR-driven lung cancer. Most recently, his collaborative study in Nature Biotechnology with Insilico Medicine and Alán Aspuru-Guzik marked a historic milestone as the first demonstration of AI- and quantum-enabled discovery of KRAS inhibitors. He is a Fellow of the Royal Society of Canada and the Croatian Academy of Sciences and Arts (HAZU), an elected member of EMBO, and the inaugural Editor-in-Chief of Elsevier’s journal Disease and Therapeutics.